Possible multiple transporters were involved in hepatobiliary excretion of antofloxacin in rats

Xenobiotica

Volumn 37, Issue 6, 2007, Pages 579-591

  Hu, J H ^a   Liu, X D ^a   Xie, L ^a   Wang, G J ^a   Liu, H Y ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Antofloxacin; Biliary excretion; Multidrug resistance associated protein 2; P glycoprotein; Quinolone antimicrobial agent

Indexed keywords

ANTIINFECTIVE AGENT; ANTOFLOXACIN; CIMETIDINE; CYCLOSPORIN A; DICLOFENAC; ERYTHROMYCIN; PROBENECID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG TRANSPORT; HEPATOBILIARY SYSTEM; MALE; NONHUMAN; PHARMACOLOGICAL PARAMETERS; RAT; STEADY STATE;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BILE; BIOLOGICAL TRANSPORT; CIMETIDINE; CYCLOSPORINE; DICLOFENAC; ENZYME INHIBITORS; ERYTHROMYCIN; LIVER; MALE; MEMBRANE TRANSPORT PROTEINS; OFLOXACIN; PROBENECID; RATS; RATS, SPRAGUE-DAWLEY; URICOSURIC AGENTS;

RATTUS;

EID: 34447132948     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701358731     Document Type: Article

References (43)

1. Akashi M, Tanaka A, Takikawa H. 2006. Effect of cyclosporin A on the biliary excretion of cholephilic compounds in rats. Hepatology Research 34:193-198.
2. Bodó A, Bakos É, Szeri F, Váradi A, Sarkadi B. 2003. Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anion. Journal of Biological Chemistry 278:23529-23537.
3. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72:248-254.
4. Chadwick RW, Copeland MF, Carlson GP, Trela BA, Most BM. 1988. Comparison of in vivo and in vitro methods for assessing the effects of carbon tetrachloride on the hepatic drug-metabolizing enzyme system. Toxicology Letters 42:309-316.
5. Chan LM, Lowes S, Hirst BH. 2004. The ABCs of drug transport in intestine and liver: Efflux proteins limiting drug absorption and bioavailability. European Journal of Pharmaceutical Sciences 21:25-51.
6. Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M, Kuwano M, Akiyama SI. 1999. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Molecular Pharmacology 56:1219-1228.
7. Dautrey S, Felice K, Petiet A, Lacour B, Carbon C, Farinotti R. 1999. Active intestinal elimination of ciprofloxacin in rats: Modulation by different substrates. British Journal of Pharmacology 127:1728-1734.
8. Dietrich CG, Geier A, Oude Elferink RPJ. 2003. ABC of oral bioavailability: Transporters as gatekeepers in the gut. Gut 52:1788-1795.
9. Faber KN, Muller M, Jasen PL. 2003. Drug transport proteins in the liver. Advanced Drug Delivery Reviews 55:107-124.
10. Hata S, Wang P, Eftychiou N, Ananthanarayanan M, Batta A, Salen G, Pang KS, Wolkoff AW. 2003. Substrate specificities of rat oatp1 and ntcp: Implications for hepatic organic anion uptake. American Journal of Physiology. Gastrointestinal and Liver Physiology 285:G829-G839.
11. Heilborna U, Rostb BR, Arboreliusc L, Brodina E. 2007. Arthritis-induced increase in cholecystokinin release in the rat anterior cingulate cortex is reversed by diclofenac. Brain Research 1136:51-58.
12. Hiroyuki K, Yuichi S. 2001. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier. Drug Discovery Today 6:150-156.
13. Hu JH, Liu XD, Xie L. 2006. An HPLC method for the determination of antofloxacin in rat plasma and bile and its pharmacokineic study. Journal of China Pharmaceutical University 37:153-156 (Chinese).
14. Huang ZH, Murakami T, Okochi A, Yumoyo R, Nagai J, Takano M. 2001. Expression and function of P-glycoprotein in rats with carbon tetrachloride-induced acute hepatic failure. Journal of Pharmacy and Pharmacology 53:873-881.
15. Khamdang S, Takeda M, Noshiro R, Narikawa S, Enomoto A, Anzai N, Piyachaturawat P, Endou H. 2002. Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal antiinflammatory drugs. Journal of Pharmacology and Experimental Therapeutics 303:534-539.
16. Liu XD, Zhang L, Xie L. 2003. Effect of P-glycoprotein inhibitors erythromycin and cyclosporin A on brain pharmacokinetics of nimodipine in rats. European Journal of Drug Metabolism and Pharmacokinetics 28:309-313.
17. Merino G, Alvarez AI, Pulido MM, Molina AJ, Schinkel AH, Prieto JG. 2006. Breast cancer resistance protein (bcrp/abcg2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metabolism and Disposition 34:690-695.
18. Mostafavi SA, Foster RT. 2003. Influence of cimetidine co-administration on the pharmacokinetics of acebutolol enantiomers and its metabolite diacetolol in a rat model: The effect of gastric pH on double-peak phenomena. International Journal of Pharmaceutics 255:81-86.
19. Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K. 2004. Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). European Journal of Pharmacology 503:25-30.
20. Murakami T, Yumoto R, Nagai J, Takano M. 2002. Factors affecting the expression and function of P-glycoprotein in rats: Drug treatments and diseased states. Pharmazie 57:102-107.
21. Murata M, Tamai I, Sai Y, Nagata O, Kato H, Sugiyama Y, Tsuji A. 1998. Hepatobiliary transport kinetics of HSR-903, a new quinolone antibacterial agent. Drug Metabolism and Disposition 26:1113-1119.
22. Nadai M, Zhao YL, Wang L, Nushio Y, Takagi K, Kitaichi K, Takagi K, Yoshizami H, Hasegawa T. 2001. Endotoxin impairs biliary transport of sparfloxacin and its glucuronide in rats. European Journal of Pharmacology 432:99-105.
23. Naruhashi K, Tamai I, Inoue N, Muraoka H, Sai Y, Suzuki N, Tsuji A. 2001. Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein. Journal of Pharmacy and Pharmacology 53:699-709.
24. Niinuma K, Kato Y, Suzuki H, Tyson CA, Weiter V, Dabbs JE, Froehlich R, Green CE, Sugiyama Y. 1999. Primary active transport of organic anions on bile canalicular membrane in humans. American Journal of Physiology 276:1153-1164.
25. Oh YH, Han HK. 2006. Pharmacokinetic interaction of tetracycline with non-steroidal anti-inflammatory drugs via organic anion transporters in rats. Pharmacological Research 53:75-79.
26. Pavek P, Merino G, Wagenaar E, Bolscher E, Novotna M, Jonker JW, Schinkel AH. 2005. Human breast cancer resistance protein: Interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b) pyridine, and transport of cimetidine. Journal of Pharmacology and Experimental Therapeutics 312:144-152.
27. Potschka H, Baltes S, Löscher W. 2004. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood-brain barrier penetration of levetiracetam in rats. Epilepsy Research 58:85-91.
28. Rodriguez-Ibanez M, Nalda-Molina R, Montalar-Montero M, Bermejo MV, Merino V, Garrigues TM. 2003. Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: In vitro and in situ inhibition studies. European Journal of Pharmaceutics and Biopharmaceutics 55:241-246.
29. Sallustio BC, Holbrook FL. 2001. In vivo perturbation of rat hepatocyte canalicular membrane function by diclofenac. Drug Metabolism and Disposition 29:1535-1538.
30. Sasabe H, Terasaki T, Tsuji A, Sugiyama Y. 1997. Carrier-mediated hepatic uptake of quinolone antibiotics in the rat. Journal of Pharmacology and Experimental Therapeutics 282:162-171.
31. Sasabe H, Kato Y, Tsuji A, Sugiyama Y. 1998a. Stereoselective hepatobiliary transport of the quinolone antibiotic grepafloxacin and its glucuronide in the rat. Journal of Pharmacology and Experimental Therapeutics 284:661-668.
32. Sasabe H, Tsuji A, Sugiyama Y. 1998b. Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats. Journal of Pharmacology and Experimental Therapeutics 284:1033-1039.
33. Shitara Y, Sato H, Sugiyama Y. 2005. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annual Review of Pharmacology and Toxicology 45:689-723.
34. 4-induced hepatic injury. Drug Metabolism and Disposition 31:482-490.
35. Strassburg CP, Barut A, Obermayer-Straub P, Li Q, Nguyen N, Tukey RH, Manns MP. 2001. Identification of cyclosporin A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase: UGT2B7. Journal of Hepatology 34:865-872.
36. Suzuki T, Zaima C, Moriki Y, Fukami T, Tomono K. 2007. P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood-brain barrier. Journal of Drug Targeting 15:67-74.
37. Uchaipichat V, Mackenzie PI, Guo XH, Gardner-Stephen D, Galetin A, Houston JB, Miners JO. 2005. Human UDP-glucuronosyltransferases: Isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metabolism and Disposition 33:1925-1926.
38. van Montfoort JE, Hagenbuch B, Groothuis GM, Koepsell H, Meier PJ, Meijer DK. 2003. Drug uptake systems in liver and kidney. Current Drug Metabolism 4:185-211.
39. Yagi Y, Shibutani S, Hodoshima N, Ishiwata K, Okudaira N, Li Q, Sai Y, Kato Y, Tsuji A. 2003. Involvement of multiple transport systems in the disposition of an active metabolite of a prodrug-type new quinolone antibiotic, prulifloxacin. Drug Metabolism and Pharmacokinetics 18:381-389.
40. Ye H, Wu JM, Yang YS, Chen KX, Ji RY. 2002. Antibacterial activities of the derivatives YH54 and YH57 of levofloxacin in vitro. Chinese Pharmacological Bulletin 18:112-113.
41. Yumoto R, Murakami T, Nakamoto Y, Hasegawa R, Nagai J, Takano M. 1999. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. Journal of Pharmacology and Experimental Therapeutics 289:149-155.
42. Zhang L, Liu XD, Wang GJ, Xie L, Wang GJ. 2003. P-glycoprotein restricted transport of nimodipine across blood-brain barrier. Acta Pharmacologica Sinica 24:903-906.
43. Zhao YL, Cai SH, Wang L, Kitaichi K, Tatsumi Y, Nadai M, Yoshizumi H, Takagi K. 2002. Possible involvement of P-glycoprotein in the biliary excretion of grepafloxacin. Clinical and Experimental Pharmacology and Physiology 29:167-172.